All In Biotech

Drug Trial Radar · NCT07739966

A Study of DS-3939a in Participants With Solid Tumors

A Phase 1b/2, Multicenter, 2-part, Open-label Trial to Evaluate DS-3939a in Participants With Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Oct 13, 2026

Primary completion

Jul 31, 2030

Study completion Jan 29, 2032

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
First posted
Jul 31, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to evaluate the safety, tolerability, and efficacy of DS-3939a in combination with other anticancer agents or as a monotherapy in participants with solid tumors.

Conditions

  • Solid Tumor
  • Locally Advanced Non-Small Cell Lung Cancer
  • Metastatic Non-Small Cell Lung Cancer

Interventions

  • DS-3939aDrug

    DS-3939a will be administered as an IV infusion.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an IV infusion.

  • CarboplatinDrug

    Carboplatin will be administered as an IV infusion.

  • PemetrexedDrug

    Pemetrexed will be administered as an IV infusion.

  • DS-1103aDrug

    DS-1103a will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During first cycle (Cycle length=21 days)
  2. Part 1: Number of Participants With TEAEsTime frame: Up to approximately 4 years
  3. Part 2: Objective Response (OR) Per RECIST v1.1 as Assessed by InvestigatorTime frame: Up to approximately 4 years

Locations

76 sites in 13 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group (Hog) - Fayetteville

    Fayetteville, Arkansas · Recruiting

  • UCLA Health

    Los Angeles, California · Not yet recruiting

  • Moffitt Cancer Center - Magnolia Campus

    Tampa, Florida · Not yet recruiting

  • Oregon Health & Science University

    Portland, Oregon · Not yet recruiting

  • Lifespan Cancer Institute - Rhode Island Hospital

    Providence, Rhode Island · Not yet recruiting

  • The University of Texas Md Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Inova Schar Cancer Institute

    Fairfax, Virginia · Recruiting

  • Instituto Alexander Fleming

    Buenos Aires, Argentina · Not yet recruiting

  • Instituto Oncologico de Cordoba (Ionc) - Fundacion Richardet Longo

    Córdoba, Argentina · Not yet recruiting

  • Sanatorio Parque

    Rosario, Argentina · Not yet recruiting

  • Cer San Juan - Centro Polivalente de Asistencia E Investigacion Clinica

    San Juan, Argentina · Not yet recruiting

  • Clinica Viedma S.A.

    Viedma, Argentina · Not yet recruiting

  • Medizinische Universitat Innsbruck

    Innsbruck, Austria · Not yet recruiting

  • Karl Landsteiner Institut Fur Lungenforschung Und Pneumologische Onkologie

    Vienna, Austria · Not yet recruiting

  • Universite Libre de Bruxelles (Ulb) - Institut Jules

    Brussels, Belgium · Not yet recruiting

  • Jessa Ziekenhuis - Hartcentrum Hasselt

    Sint-Truiden, Belgium · Not yet recruiting

  • Fundacao Pio Xii-Hospital de Cancer de Barretos

    Barretos, Brazil · Not yet recruiting

  • Liga Norte Riograndense Contra O Cancer - Pesquisa Clinica

    Natal, Brazil · Not yet recruiting

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Brazil · Not yet recruiting

  • Hospital Sao Lucas Da Pucrs

    Porto Alegre, Brazil · Not yet recruiting

  • Obras Sociais Irma Dulce - Centro de Pesquisa Oncologica E Clinica (Cpoc)

    Salvador, Brazil · Not yet recruiting

  • Hospital Israelita Albert Einstein

    São Paulo, Brazil · Not yet recruiting

  • Beijing Chest Hospital, Capital Medical University

    Beijing, China · Not yet recruiting

  • Jilin Cancer Hospital

    Changchun, China · Not yet recruiting

  • Hunan Cancer Hospital

    Changsha, China · Not yet recruiting

  • The First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine (Zhejiang Provincial First Hos

    Hangzhou, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute and Hospital

    Hexi District, Tianjin, China · Not yet recruiting

  • Jiamusi Cancer Hospital

    Jiamusi, China · Not yet recruiting

  • Shandong University - Shandong Cancer Hospital

    Jinan, China · Not yet recruiting

  • Lin Yi Cancer Hospital

    Linyi, China · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, China · Not yet recruiting

  • Taizhou Hospital of Zhejiang Province

    Taizhou, China · Not yet recruiting

  • Hubei Cancer Hospital

    Wuhan, China · Not yet recruiting

  • Henan Provincial Cancer Hospital

    Zhengzhou, China · Not yet recruiting

  • Aphm - Hopital Nord

    Marseille, France · Not yet recruiting

  • Centre Hospitalier Universitaire de Montpellier (Chu Montpellier) - Hopital Lapeyronie

    Montpellier, France · Not yet recruiting

  • Hospitalier Paris Saint-Joseph

    Paris, France · Not yet recruiting

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.